Global Spinal Surgery Devices And Equipment Market

The 3D printed medical devices market consists of sales of 3D printed medical devices and related services. 3D printing is a process to create three-dimensional medical devices with the help of computer-aided design. Some of the 3D printed medical devices include orthopaedic and cranial implants, surgical instruments, dental restorations such as crowns, and external prosthetics. The main types of 3D printed medical devices are implants, surgical instruments, prosthetics, tissue engineering devices, and others. The 3D-printed implants are medical implants that are made using 3D printing technology to create complex geometries. These are made up of raw materials such as plastics, biomaterial inks, and metals and alloys. The technologies involved in 3D printed medical devices are fused deposition modeling, digital light processing, stereolithography, and selective laser melting. These provide applications in orthopedic, spinal, dental, hearing aids, and others that are used by end-users such as hospitals, diagnostics centers, academic institutions, and others. The global 3D printed medical devices market size is expected to grow from $2.29 billion in 2021 to $2.76 billion in 2022 at a compound annual growth rate (CAGR) of 20.4%. The global 3D printed medical device market size is then expected to grow to $4.49 billion in 2026 at a CAGR of 13.0%. The increasing prevalence of osteoarthritis and similar musculoskeletal conditions is one of the major factors driving the growth of the 3D printed medical devices market. Osteoarthritis is a disorder that damages the joint cartilage and surrounding tissues causing pain, stiffness, and loss of joint function to the person affected by it. The 3D printing medical devices enable the creation of a replica of a patient's joint which can provide surgeons with a crucial piece of information that might not be visible on a 2-dimensional scan. The chance of developing osteoarthritis increases with age. For instance, according to the US National Library of Medicine report, by 2040, it is estimated that approximately 78 million (26%) US adults aged 18 years and above will be projected to have doctor-diagnosed arthritis. Thereby driving the adoption of 3D printed medical devices, positively impacting the market growth. Biocompatibility issues related to 3D printed medical devices restrict the growth of the 3D printed medical devices market. Biocompatibility implies the properties that make material or a device compatible with the human body. If the material used for the preparation of a 3D printed implant device is not compatible with the patients' biomechanics, then patients may suffer side effects such as abnormal growth of bone and bleeding. Among the most common metal used in the manufacturing of 3D printed medical devices is Titanium. Though Titanium offers reliability and accuracy in creating medical-grade products, some human bodies tend to reject titanium as its chemical composition can inhibit the bone and tissue from interacting with the implant. Apart from these other reasons which may contribute to the failure of metallic implants that are either caused by the material properties of the metal (e.g., high stiffness, high corrosion rate, and toxicity) itself or by the exposure of the bone to infected metal implants i.e., infection. The increasing use of 3D printing technology in the spine industry is one of the latest trends in the 3D printing medical devices market. The spine industry is adopting 3D printing to produce new innovative products that can promote bone ingrowth and improve implant fixation to spine bone, reducing the number of manufacturing steps, thereby making the 3D printing process more cost-effective in several cases. For instance, Medtronic launched its titanium 3D printed platform – TiONIC Technology. TiONIC Technology is a 3D printed technique that uses laser methods to create implants with enhanced surface textures. Artic-L is the first implant created by the company using TiONIC Technology. The implant is made up of titanium and designed to be used by surgeons in spine surgery. In addition to that, K2M’s Lamellar, introduced its 3D Titanium Technology to create a 3D spinal implant. The 3D printing medical device using titanium technology uses an advanced 3D printing method to create structures that were once considered impractical with traditional manufacturing techniques. The implants use titanium powder and are associated with bone growth activity. Food and Drug Administration (FDA) has a Centre for Device and Radiological Health (CDRH) to regulate the firm which manufacture, repackage, relabel and/or import 3D printing medical devices in the US. FDA provides manufacturers with a draft with guidance that includes recommendations for device design, manufacturing, and testing considerations during the development of 3D printing medical devices. Section F of the 'Technical Considerations for Additive Manufactured Medical Device' draft, requires the manufacturers to evaluate the biocompatibility of the final finished device as described in the guidance "Use of International Standard ISO-10993". The guidelines also require the manufacturer of the 3D printing devices to mention the additional information in the label if any toxic chemical additives such as certain additives, catalysts, binding and curing agents, uncured monomers, and plasticizers are used in making 3D printing medical devices. In July 2020, Medtronic, an American Irish-domiciled medical device company acquired Medicrea International for an undisclosed amount. The acquisition of Medicrea expands Medtronic’s already deep portfolio as this adds to their spinal solution profile as the advent of new digital technology will offer the ability to custom spinal implants. Medicrea International is a spinal surgery company with 30+ FDA-approved spinal implant technologies that have been utilized in over 150,000 spinal surgeries to date. Major players in the 3D printed medical devices market are 3D Systems Corporation, EnvisionTEC, Stratasys Ltd., Arcam AB, Cyfuse Biomedical, Materialise NV, Organovo Holdings, EOS GmbH, FabRx Ltd., and Concept Laser. The regions covered in the global 3D printed medical devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the 3D printed medical devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global 3D printed medical devices market is segmented - 1) By Type: Implants, Surgical Instruments, Prosthetics, Tissue Engineering Devices, Others 2) By Application: Orthopedic, Spinal, Dental, Hearing Aids, Others 3) By Technology: Fused Deposition Modelling, Digital Light Processing, Stereolithography, Selective Laser Melting 4) By Raw Material: Plastics, Biomaterial Inks, Metals and Alloys 5) By End-User: Hospitals, Diagnostics Centres, Academic Institutions, Others

The cerebrospinal fluid (CSF) management devices and equipment market consist of sales of cerebrospinal fluid management devices and equipment and related services. CSF devices and equipment are used in the treatment of hydrocephalus, a condition of excessive accumulation of CSF within the head. The main types of cerebrospinal fluid (CSF) management devices and equipment are CSF shunts and CSF drainage systems. CSF shunts are the devices used for hydrocephalus treatment. They consist of silastic tubes that divert CSF from the ventricles to other body cavities, like the peritoneum, the right cardiac atrium, or the pleural space. The CSF drainage systems types such as ventricular drainage system and lumbar drainage system are used by age groups such as pediatric, adult, and geriatric. The various end-users are hospitals and ambulatory surgical centers. The global cerebrospinal fluid management devices and equipment market size is expected to grow from $0.86 billion in 2021 to $0.93 billion in 2022 at a compound annual growth rate (CAGR) of 8.0%. The global CSF devices and equipment market size is expected to grow to $1.2 billion in 2026 at a CAGR of 6.7%. The increase in the number of brain surgeries drives the market for cerebrospinal fluid (CSF) devices. CSF devices play a major role in the treatment of traumatic brain injury (TBI), shunts are devices used in the CSF procedure which ensure that any cerebrospinal fluid accumulated near the brain gets drained out. In the United States, one of the leading causes of death is TBI and approximately 1.5 to 2 million adults and children suffer a traumatic brain injury (TBI) each year. Among the 1.1 million who face head injury, 235,000 individuals will be hospitalized with a moderate to severe head injury while approximately 50,000 face death. However, a majority of them will have a mild injury that does not require admission to the hospital. With such an increase in the number of brain injuries, the CSF devices market will continue to grow. The high possibility of shunt failure or malfunctioning is a major factor restraining the cerebrospinal fluid (CSF) devices market. Shunts are devices used to restrict Hydrocephalus, which is a condition where there is an excess accumulation of cerebrospinal fluid (CSF) near the brain which can cause loss of brain tissues and even impair the brain. According to the 2019 pediatric emergency medicine reports, approximately 40% of shunts fail within the first year and about 56–80% of all shunts fail by 10 years. Reports show that shunt blockages occur in about 31% of patients. Due to such a high failure rate of shunts, it causes trust deficiency in patients, and as a result, patients look for alternative treatments. Implementing new and improved sensors is the latest trend in the cerebrospinal fluid devices market, this may provide the market with the much-needed boost to improve its growth rate while at the same time improving the quality of the diagnosis. Treatment of Hydrocephalus, which is a condition where there is an excess accumulation of CSF near the brain is a very complex process with many complications. High precision devices are required to improve the quality and success rate of shunt treatments, with the help of technology, new sensors, and telemetry devices are being explored. A cutting-edge new sensor has been developed by the Rogers research group at Northwestern University, Illinois. Researchers at Northwestern believe that their latest skin sensor can greatly reduce malfunctions and the number of brain surgeries. The sensor uses body temperature readings to give information about how much cerebrospinal fluid is leaking. This sensor gives different heat signatures depending on whether the shunt is functional or not. This is a major development in the CSF market, the sensor also enables access to information that was previously inaccessible. Currently, the US Food and Drug Administration (FDA) identifies CSF devices as class II devices. As per section 21, subsection 510K certain protocol has to be followed before these devices can be approved. The firms have to list down any possible risks to health and measures taken by them so that the device addresses such health hazards. Apart from this a cover sheet stating that the device is a class II device, a brief description of the device, and a summary report of what the device does and the scope of the device must be duly stated. The last step verifies the device for biocompatibility, performance, and appropriate labeling such as expiration dates, prescriptions, etc. The stringent regulatory guidelines may take time for the product release and increase the overall development cost of the product, thereby impacting the market. Major players in the cerebrospinal fluid (CSF) management devices and equipment market are B. Braun, DePuy Synthes, Integra Life Sciences, Medtronic, Sophysa, BeckerSmith Medical Inc, Möller Medical GmbH, Spiegelberg GmbH & Co. KG, Dispomedica GmbH, and Terumo Corporation North America was the largest region in the cerebrospinal fluid (CSF) management devices and equipment market in 2021. Asia Pacific was the second-largest region in the global cerebrospinal fluid management devices and equipment market. The regions covered in the global CSF devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the CSF management devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The global cerebrospinal fluid management (CSF) devices and equipment market is segmented - 1) By Type: CSF Shunts, CSF Drainage Systems 2) By End-User: Hospitals, Ambulatory Surgical Centers 3) By Age Group: Pediatric, Adult, Geriatric 4) By Drainage System Type: Ventricular Drainage System, Lumbar Drainage System

The implantable drug delivery devices market consists of sales of implantable drug delivery devices and related services by companies that manufacture them. Implantable drug delivery devices are drug delivery systems implanted by surgery to allow site-specific drug administration at the tissue or organ where the drug is most needed. The main product of implantable drug delivery devices is contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and others. Spinal implants are devices that are used by surgeons while performing surgery to treat deformity, stabilize and strengthen the spine, and facilitate fusion. The technologies involved are diffusion, osmotic, magnetic, and others. The various applications involved are contraception, ophthalmology, cardiovascular, diabetes, oncology, autoimmune diseases, and others. The global implantable drug delivery devices market size is expected to grow from $17.20 billion in 2021 to $18.35 billion in 2022 at a compound annual growth rate (CAGR) of 6.7%. The global implantable drug delivery market is then expected to grow to $24.08 billion in 2026 at a CAGR of 7.0%. The rise in the incidence of target diseases such as diabetic retinopathy, cancer, cardiovascular diseases, and other chronic diseases is expected to drive the implantable drug delivery devices market. According to the International Diabetes Federation (IDF), the global prevalence of diabetic retinopathy was around 27% in 2019. Implantable drug delivery devices are used for site-specific drug administration where the drug is most needed, such as Gliadel® wafer as an implant used in the treatment of brain tumors, Lupron depot for the treatment of prostate cancer. Hence, the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market. The rising number of product recalls and lawsuits associated with implantable drug delivery devices is expected to hinder the market. In the past few years, there had been an increase in product recalls and lawsuits connected with these devices. For instance, in December 2019, around 7,000 Medtronic SynchroMed II, implantable drug infusion pumps were recalled due to the presence of foreign bodies in them. Nexplanon, a small rod contraceptive implant inserted into the skin of the upper arm to prevent pregnancy for up to three years, is facing a lawsuit, and lawyers and attorneys at National Injury Help have been investigating all such cases against those injured by Nexplanon. Therefore, the rising number of product recalls and lawsuits concerning implantable drug delivery devices is expected to hinder the growth of the market. Companies and researchers are focusing on developing 3D implantable drug delivery devices. 3D printed titanium transcutaneous ports are implanted behind the patient's ear, allowing healthcare professionals to access the catheters. For instance, in February 2020, Renishaw and Herantis Pharma announced the award-winning device, which received positive results in phase 2 trials, that consists of up to four catheters implanted in the relevant brain areas. Researchers at King Abdullah University of Science and Technology have introduced a miniaturized drug delivery system suitable for in-vivo biomedical applications. The system consists of an electrolytic pump, which operates a micro bellows membrane as an actuator for delivery through microneedles. A two-photon 3D printing technique was used to make a reservoir equipped with a microneedle. In November 2019, Dare Bioscience, a USA-based biopharmaceutical company with a special focus on women's health, has acquired Microchips Biotech for an amount of $102 million. Through this acquisition, Microchips has become the wholly subsidiary of Dare Bioscience. Microchips Biotech is a USA-based company developing innovative drug implants. Major players in the implantable drug delivery devices market are Allergan Inc, Bayer HealthCare, Medtronic Inc, Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc, Merck, Genetech Inc, and Psivida. North America was the largest region in the implantable drug delivery devices market in 2021. Asia Pacific was the second-largest region in the global implantable drug delivery device market during the forecast period. The regions covered in the global implantable drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the implantable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global implantable drug delivery devices market is segmented - 1) By Product: Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-Absorbable Stents, Intraocular Stents, Infusion Pumps, Others 2) By Technology: Diffusion, Osmotic, Magnetic, Others 3) By Application: Contraception, Ophthalmology, Cardiovascular, Diabetes, Oncology, Autoimmune Diseases, Others

The anesthetics market consists of sales of drugs that cause a relaxing sensation to calm patients during surgery and remove the sensation of pain. These drugs are used to give a sense of calm to patients through muscle relaxation which also causes amnesia. The main types of anesthetics are general anesthetics and local anesthetics. A medically induced coma with lack of defensive reflexes is known as general anaesthesia. It is caused by the injection of one or more general anaesthetic drugs. The different routes of administrations include inhalation anaesthesia drugs, intravenous anaesthesia drugs, topical anaesthesia drugs and is used in various applications such as general surgeries, plastic surgery, cosmetic surgeries, dental surgeries, other applications. The global anesthetics market size is expected to grow from $9.24 billion in 2021 to $9.88 billion in 2022 at a compound annual growth rate (CAGR) of 7.0 %. The change in the anesthetics market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $12.24 billion in 2026 at a CAGR of 5.5%. The increase in the number of surgeries is one of the major drivers of the anesthetics market due to the applications of anesthetic drugs during surgical procedures. This rise is mainly due to increasing incidents of injuries and accidents that require surgeries. For example, according to WHO's Global status report on road safety, the number of road accidents reached 1.35 million, with approximately 64 deaths for every 100,000 vehicles. Stringent guidelines and regulations imposed by regulatory bodies are one of the important restraints for the anesthetics market. These guidelines include conducting clinical trials of newly developed drugs, standards related to patient safety, and monitoring of patients under anesthesia. Complying with these guidelines and getting regulatory approvals consumes a lot of time and negatively impacts the growth of the anesthetics market. For example, the American Society of Anesthesiologists imposes various standards that apply to anesthesia care and monitoring of patients including standards for pre-, basic- and post-anesthesia care and monitoring. Increasing consolidation in the form of acquisitions is an emerging trend in the anesthetics market. This is mainly due to the high level of R&D and intellectual property (IP) investment needed to establish companies that manufacture anesthetic drugs. In this regard, mergers and acquisitions are considered as time and cost-effective methods. Some of the notable acquisitions in recent years include the acquisition of MyoScience by Pacira for $220 million in 2019, acquisition of Claris Injectables by Baxter for $625 million, acquisition of GSK's anesthetics portfolio by Aspen for $238.7 million, and acquisition of Hospira by Pfizer for $17 billion. Major players in the anesthetics market are Baxter, Abbott Laboratories, AstraZeneca, F. Hoffmann-La Roche AG, B. Braun Melsungen AG, AbbVie Inc., Hospira, Aspen, Boehringer Ingelheim International GmbH and Eisai Co. Ltd. North America is the largest region in the anesthetics market in 2021. The Middle East is expected to be the fastest growing region in the global anesthetics market during the forecast period. The regions covered in the global anesthetic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anesthetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global anesthetics market is segmented - 1) By Type: General Anesthetics, Local Anesthetics 2) By Application: General Surgeries, Plastic Surgery, Cosmetic Surgeries, Dental Surgeries, Others 3) By Route of Administration: Inhalation Anaesthesia Drugs, Intravenous Anaesthesia Drugs, Topical Anaesthesia Drugs 4) By Local Anesthetics: Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Articaine, Benzocaine, Others 5) By General Anesthetics: Propofol, Sevoflurane, Desflurane, Dexmedetomidine, Remifentanil, Midazolam, Others

The market for spine implants consists of sales of inserts used in spinal surgery. Spine implants are the devices used to correct the deformity in the spine, stabilize and strengthen the spine and facilitate fusion of bones in different disorders such as degenerative disc disease, kyphosis, scoliosis, spondylolisthesis, spinal stenosis, and fracture. The market consists of revenue generated by the companies manufacturing spine implants by the sales of these products. The main products in the spine implants are spinal fusion devices, non-fusion devices/motion preservation devices, vertebral compression fracture (VCF) treatment devices, spinal bone stimulators, spine biologics. The spinal fusion devices provide a solution for spinal instability and are designed specifically to treat spinal disorders and use surgical procedures to implant titanium-alloy, titanium, stainless steel, and non-metallic devices into the spine. The various procedures involved are open surgery, minimally invasive surgery (MIS). The various materials in spine implants include metallic, polymeric, and ceramic. The spinal implants are used in hospitals, specialty orthopedic and spine centers, and ambulatory surgical centers. The global spine implants market size is expected to grow from $10.50 billion in 2021 to $11.32 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The global spine implant market size is expected to grow to $15.77 billion in 2026 at a CAGR of 8.6%. The rising incidences of spinal disorders coupled with the usage of minimally invasive surgical procedures are contributing to the growth of the global spinal implants market. According to Branko PRPA, surgical in September 2021, annually there are 1.34 to 4.6 spinal cases per million and 1,400 new cases diagnosed each year, with 33,000 having some type of disability in the US and among them, 30% of the adult female population suffers from lower back pain, compared to 25 percent of the adult male adult population and this is approximately 31% of men acknowledged that their condition affects their employment compared to 20% of women. In 2019, 30% of the US population suffered from lower back problems in the last three months. And due to the emergence of minimally invasive spine surgical (MISS) approaches, it has now become feasible and efficient for treating a wide range of spinal disorders without long incisions and by avoiding significant damage to muscles surrounding the spine, thereby resulting in fewer post-operative pains and faster recovery. Therefore, the increased prevalence of spinal disorders along with the ease in treatment by MISS approaches is driving the global spinal implants market. The increased treatment procedural cost is acting as a hindrance to the global spinal implants market growth. According to a study published in 2019 in National Center for Biotechnology Information, 1862 patients underwent different spinal surgeries and the direct cost (preoperative consultation, imaging studies, hospital costs, medical fees, implants, physical medicine treatments, ambulance transfers, and post-surgery follow up costs) of all spinal interventions for 1,862 patients in 1 year was $12,389,960. The cost of spinal surgeries has increased by 175% globally and in the US, the annual cost of spine care is estimated at $105 billion per patient annually. Increased treatment procedural costs will increase monetary concerns, limiting the market growth. The innovation of implants in providing minimally invasive and motion-preserving stabilization is a major trend in the spine implants market. For example, RTI Surgical Holdings, a global surgical implant company, has launched the first and only posterior lumbar motion preservation solution, Coflex. Coflex is a differentiated, minimally-invasive, motion-preserving stabilization implant that is FDA PMA-approved for the treatment of moderate to severe lumbar spinal stenosis (LSS). It can be directly implanted following a surgical decompression, without fusing the bones. The device comes in different sizes to fit the patient’s anatomy, and this can be performed even in an outpatient setting. In June 2019, Medtronic completed the acquisition of Titan Spine for an undisclosed amount. Ireland-based Medtronic is a world leader in medical technology, services, and solutions whereas Titan Spine is a Mequon-based medical device developer pioneered in titanium interbody fusion devices featuring a surfacing technology. Interbody implants are spacers that can be inserted between the vertebrae during spinal fusion surgery to help relieve pressure on nerves and hold the vertebrae in place while the fusion occurs. Medtronic maintains its position as a leading innovator in procedural solutions for spine surgery by the acquisition of Titan Spine. Now, Medtronic’s spine division, a part of Restorative Therapies Group, expands its existing spine technologies by adding Titan Spine’s products to its portfolio. Major players in the spine implants market are Medtronic, Depuy Synthes, Johnson & Johnson, Stryker Corporation, NuVasive, Inc., Zimmer Biomet Holdings, Globus Medical, Alphatec Holdings, Orthofix International, and RTI Surgical. The regions covered in the global spine implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the spine implant market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global spine implants market is segmented - 1) By Product: Spinal Fusion Devices, Non-Fusion Devices/Motion Preservation Devices, Vertebral Compression Fracture (VCF) Treatment Devices, Spinal Bone Stimulators, Spine Biologics 2) By Procedure: Open Surgery, Minimally Invasive Surgery (MIS) 3) By Material: Metallic, Polymeric, Ceramic 4) By End-Use: Hospitals, Specialty Orthopedic And Spine Centers, Ambulatory Surgical Centers

The surgical equipment market consists of sales of surgical equipment and related services by entities (organizations, sole traders, and partnerships) that produce surgical equipment used during surgeries. The main types in the surgical equipment are surgical sutures and staples, handheld surgical devices and equipment, electrosurgical devices, and equipment. The surgical sutures also known as stitches, are sterile surgical threads used to repair cuts. They are used to close incisions in surgery. Staples is a town used as a center for the sale or exportation of commodities in bulk. The type of expenditure is public, private. The products used are instruments/equipment, disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The global surgical equipment market size is expected to grow from $24.53 billion in 2021 to $26.89 billion in 2022 at a compound annual growth rate (CAGR) of 9.6%. The global surgical equipment market size is then expected to grow to $36.42 billion in 2026 at a CAGR of 7.9%. Growing demand for minimally invasive surgery (MIS) will increase the demand for advanced surgical equipment. An MIS refers to any surgical procedure that requires minimal incisions as opposed to traditional or open surgery used for the same purpose. Preference for MIS procedures increased due to their multiple advantages such as short healing and recovery time, minimal scarring, cost-effectiveness, minimal trauma and pain, and decreased risk of infections and complications. Medical technology innovations led to the development of advanced surgical equipment such as Da Vinci surgical systems, C-arm devices, electrosurgical and power-assisted surgical equipment. These devices which enable MIS will drive the surgical equipment market during the forecast period. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period, this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research, and development of new products. For instance, the US interest rates are expected to rise to 3.5% by 2021. These factors are expected to have a negative impact on the market as borrowing money becomes expensive, making it harder for companies in the surgical equipment market to raise funds for developing new devices thereby affecting the market growth. Surgical equipment manufacturers are offering next-generation ultrasonic surgical devices to simplify complex surgical procedures. Modern ultrasonic surgical devices are multifunctional instruments capable of performing tissue plane dissection, coagulation, and transection during laparoscopic or open surgical procedures. Next-generation ultrasonic devices feature adaptive tissue technology. In this technology ultrasonic algorithm actively monitors the condition of the tissue within the jaws of the device and allows the system to intelligently sense and respond to changes in patient tissue conditions. The system modulates energy delivery based on tissue thickness and tissue type to optimize vessel sealing and provide for secure and reliable large vessel sealing. Ethicon’s Harmonic devices feature adaptive tissue technology Major companies in the surgical equipment market include Johnson & Johnson (J&J), Stryker Corporation, Intuitive Surgical, B. Braun Melsungen AG, and Getinge Group. North America was the largest region in the global surgical equipment market in 2021. Western Europe was the second-largest region in the global surgical equipment market. The regions covered in the global surgical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the surgical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The global surgical equipment market is segmented - 1) By Type: Surgical Sutures and Staples, Handheld Surgical Devices and Equipment, Electrosurgical Devices and Equipment 2) By End-User: Hospitals and Clinics, Diagnostic Laboratories, Others 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

The surgical imaging arms market consists of sales of surgical imaging arms and related services by entities (organizations, sole traders, and partnerships) that manufacture surgical imaging arms, a vital component used in the field of surgery, especially for performing minimally invasive procedures. The revenue generated by the entities primarily engaged in research, development, manufacturing, and marketing of surgical imaging arms is included in the market. The main types of surgical imaging arms are G-arm surgical imaging devices, C-arm surgical imaging devices, and O-arm surgical imaging devices. The G-arm surgical imaging devices are fluoroscopic X-ray devices that are used for diagnostic imaging and minimally invasive surgical procedures. The various technology involved is image intensifier C-arms and flat-panel detector C-arms. The various application involved are orthopedic and trauma surgeries, neurosurgeries, cardiovascular surgeries, gastrointestinal surgeries, and other applications. The end-users are hospitals and ambulatory surgical centers, and academic research institutes. The global surgical imaging arms market size is expected to grow from $1.15 billion in 2021 to $1.22 billion in 2022 at a compound annual growth rate (CAGR) of 6.0%. The global surgical imaging arm market size is expected to grow to $1.6 billion in 2026 at a CAGR of 7.0%. High demand for mini C-arms devices is expected to boost market growth during the forecast period. Globally, companies are engaged in the development and manufacturing of novel equipment that assists surgeons in carrying out surgical procedures smoothly and efficiently. The rising demand for mini C-arms devices can be attributed to features, such as its miniaturized size, easy adaptability in the operation theatre, and lower price than other types of C-arms. For instance, In September 2019, OrthoScan Inc. launched TAU 2020 Mini C-arm which introduces the largest screen on the mini C-arm. Minimally invasive tests or surgeries incur low costs and save between $280 million and $340 million in the USA alone by opting for it. With this, the doses can be saved by minimizing shots to enhance work efficiency. Thus, the rising demand for mini C-arms combined with its easy-to-use features is expected to drive market growth. The high cost of surgical imaging arms is anticipated to hamper market growth during the forecast period. Recently, the prices of surgical arms are increasing owing to constant research and development to introduce new features in the devices. The price of C-arm imaging devices ranges from $25,000 to greater than $70,000. The advanced C-arms such as Siemens Cios Fusion of Siemens Healthcare and OEC 9900 of GE Healthcare range between $1,50,000 and $2,00,000. The average refurbished mini C-arm price ranges between $19,000 and $50,000. Health care settings face challenges with the high costs of these devices that are predicted to hinder the market growth. Integration of technology for real-time visualization during surgeries is gaining significant popularity in the surgical imaging arms market. With the increasing number of patients requiring surgeries, the scope and complexity of surgical interventions such as image-guided minimally invasive surgery continue to surge. In January 2020, Philips announced major innovations in its Zenition mobile C-arm platform. With the new user interface, the clinician will be able to operate C-arm inside the sterile field, reducing the communication burden with the operator and making it more intuitive to control the system. Moreover, the platform is extended to integrate intravascular ultrasound (IVUS) for peripheral vascular procedures for improving workflow and streamlining the operating room. In 2019, FUJIFILM Corporation, Japan-based multinational photography, medical equipment, and biotechnology company that leverages its imaging and information technology for innovation in healthcare, graphic arts, optical devices, highly functional materials, and other high-tech areas, planned to acquire Hitachi's diagnostic imaging-related business for approximately $1.63 billion (JPY 179 Billion). Fujifilm will further expand its Medical Systems business by applying its proprietary image processing and AI technologies to Hitachi’s extensive product portfolio. Hitachi, Ltd., is a Japan-based multinational conglomerate company that provides solutions using a diagnostics imaging system, IT, and electronic health record. Major players in the surgical imaging arms market are GE Healthcare, Hologic Inc, ATON GmbH, Whale Imaging Inc, Siemens Healthcare, Shimadzu Corp, Canon Medical Systems Corporation, Medtronic plc, Ziehm Imaging, and Philips Healthcare. The regions covered in the global surgical imaging arms market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the surgical imaging market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global surgical imaging arms market is segmented - 1) By Product Type: G-Arm Surgical Imaging Devices, C-Arm Surgical Imaging Devices, O-Arm Surgical Imaging Devices 2) By Technology: Image Intensifier C-Arms, Flat Panel Detector C-Arms 3) By Application: Orthopaedic and Trauma Surgeries, Neurosurgeries, Cardiovascular Surgeries, Gastrointestinal Surgeries, Others 4) By End-User: Hospitals and Ambulatory Surgical Centers, Academic Research Institutes

The minimally invasive surgical instruments market consists of sales of minimally invasive surgical instruments by entities (organizations, sole traders, and partnerships) that are used for performing less traumatic surgeries for the patients. Minimally invasive surgery is performed by using small incisions (cuts) and a few stitches. During the surgery, one or more small incisions are made in the body, in order to guide the surgery, a laparoscope (thin, tube-like equipment with a light and a lens for seeing) is introduced through one of the openings. Minimally invasive surgery results in less discomfort, scarring, and tissue damage, as well as a faster recovery time than traditional surgery. The minimally invasive surgical instruments include handheld instruments; inflation systems; cutter instruments; guiding devices; electrosurgical devices; auxiliary instruments. These are used for 2 types of procedure outlook that include robotic; non- robotic, in various applications such as cardiothoracic surgery; gastrointestinal surgery; orthopedic surgery; gynecological surgery; cosmetic & bariatric surgery; vascular surgery; urological surgery. These are used by various end users such as hospitals; ambulatory surgical clinics; research institutes. The global minimally invasive surgical instruments market size is expected to grow from $30.32 billion in 2021 to $32.57 billion in 2022 at a compound annual growth rate (CAGR) of 7.4%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The minimally invasive surgical instrument market is expected to reach $43.35 billion in 2026 at a CAGR of 7.41%. The rise in the number of surgical procedures is expected to propel the growth of the minimally invasive surgical instruments market. Medical practitioners prefer minimally invasive surgery over open surgery as they cause less harm and pain to human body. Minimally invasive surgery is commonly used in adrenalectomy, brain surgery, heart surgery, kidney transplant, spine surgery, plastic and cosmetic surgery. According to the International Society of Aesthetic Plastic Surgery survey, in 2019, the number of plastic surgeries performed worldwide stood at 11.3 million. According to the Organization for Economic Co-operation and Development, in 2019, the total number of coronary artery bypass graft surgical procedures in the United Kingdom stood at 14,848, and 45,398 in Germany. Therefore, the increase in the number of surgical procedures is driving the growth of the minimally invasive surgical instruments market. The development of low-cost surgical robotic systems is a key trend gaining popularity in the minimally invasive surgical instruments market. Due to the growth prospects for minimally invasive surgery in a variety of medical domains, robot-assisted surgery has fast grown in popularity. As the market for robotic surgery approaches a decade of commercial use, new surgical modalities with new technologies, smaller dimensions, and lower costs are becoming accessible. In October 2020, CMR Surgical, a UK-based medical technology company has launched Versius Surgical Robotic System at Argenteuil Hospital, a public health center near Paris, France. Versius was built by CMR Surgical to be versatile and cost-effective, using financial models that provide budget certainty and encourage regular usage of the system. Versius seeks to ensure that surgeons and hospitals are able to give the greatest level of surgical care to their patients. It has been utilised at Argenteuil Hospital for a variety of treatments in a variety of specialties. Urological and gynaecological surgery are two examples. These treatments are frequently complicated and can take several hours to complete. In these circumstances, using robotic MAS can reduce physical strain on the surgeon, cut patient recovery time from weeks to days, and lessen the risk of surgical site infections. In April 2021, Erbe Elektromedizin, a Germany-based surgical tool, and device manufacturer signed an agreement to acquire Maxer Endoscopy for an undisclosed amount. Through this acquisition, Erbe is expected to develop its surgical endoscopy business and it will also enable Erbe to provide increased performance in endoscopic and open operations using 4K and fluorescence-guided devices. Maxer, a German-based company founded in 2004, specializes in minimally invasive surgery (MIS). Maxer focuses on the development of high-end visualisation technologies that can produce dazzling, pin-sharp multi-spectral images for NIR fluorescence-guided surgery as well as ordinary white light images. Major players in the minimally invasive surgical instruments market are Abbott Laboratories, Inc, Aesculap Inc, AMNOTEC International Medical GmbH, Applied Medical Resources Corporation, B. Braun Melsungen AG, Becton, Dickinson and Company, Boston Scientific Corporation, CONMED Corporation, EndoMed Systems GmbH, FUJIFILM Holdings Corporation, HOYA Corporation, Intuitive Surgical, Inc., KARL STORZ SE & Co. KG, KLS Martin Group, Koninklijke Philips N.V., Microline Surgical, NuVasive, Inc., Olympus Corporation, Scanlan International, Inc., Smith & Nephew plc, Ethicon Inc, and GE Healthcare. North America was the largest region in the minimally invasive surgical instruments market in 2021. Asia-Pacific is the expected to be the fastest growing region in the minimally invasive surgical instruments market. The regions covered in the minimally invasive surgical instruments market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the minimally invasive surgical instruments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global minimally invasive surgical instruments market is segmented - 1) By Product: Handheld Instruments, Inflation Systems, Cutter Instruments, Guiding Devices, Electrosurgical Devices, Auxiliary Instruments 2) Type of Procedure Outlook: Robotic, Non-Robotic 3) By Application: Cardiothoracic Surgery, Gastrointestinal Surgery, Orthopedic Surgery, Gynecological Surgery, Cosmetic and Bariatric Surgery, Vascular Surgery, Urological Surgery 4) By End-User: Hospitals, Ambulatory Surgical Clinics, Research Institutes